Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

30

Revenue 2017

Botox/Neuromodulator

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Botox/Neuromodulator was produced by Allergan.

Allergan resists Valeant's advances

Allergan resists Valeant's advances Botox (onabotulinumtoxinA) and other specialty drugs, according to documents published by Valeant yesterday.

Valeant offers $45.7bn for Botox firm Allergan

Valeant offers $45.7bn for Botox firm Allergan Adding Allergan to its stable would bring a thoroughbred in the form of blockbuster wrinkle-reducer Botox (onabotulinumtoxinA), which account for almost $2bn of Allergan's total net sales of

ASA bans two Botox ads

ASA bans two Botox ads The Independent Healthcare Advisory Service (IHAS) challenged each company's reference to Botox on its respective website homepage. ... the requirement to attend a consultation with a healthcare professional to determine the suitability of Botox.

ABPI reprimands for four pharma firms

ABPI reprimands for four pharma firms Publicly reprimanded by the Prescription Medicines Code of Practice Authority, Allergan successively failed to comply with an undertaking, continuing to claim that Vistabel/Botox was clinically more potent than Bocouture/Xeomin.

Hospira CEO joins board of Kythera

Hospira CEO joins board of Kythera He joined the company following a 16-year stint at Botox developers Allergan, serving as president from 2006. ... This experience in aesthetic products such as Botox will serve him well in his role at Kythera, with the company currently developing

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics